• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Sheikh, Hamid Y
    Valle, Juan W
    Palmer, Karen
    Sjursen, Ann-Marie
    Craven, Olive
    Wilson, Gregory
    Swindell, Ric
    Saunders, Mark P
    Affiliation
    Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK.
    Issue Date
    2007-01-15
    
    Metadata
    Show full item record
    Abstract
    The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mg m(-2) on day 1, oxaliplatin 85-100 mg m(-2) on day 15 and UFT 200-300 mg m(-2) day(-1) with LV 90 mg day(-1), days 1-21 of a 28-day cycle. Patients were treated in cohorts of three. At the highest dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 300 mg m(-2) day(-1)), three of four patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2 toxicities at the maximum tolerated dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 250 mg m(-2) day(-1)). There were no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for patients with advanced colorectal cancer. We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies.
    Citation
    Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. 2007, 96 (1):38-43 Br. J. Cancer
    Journal
    British Journal of Cancer
    URI
    http://hdl.handle.net/10541/71937
    DOI
    10.1038/sj.bjc.6603521
    PubMed ID
    17213824
    Type
    Article
    Language
    en
    ISSN
    0007-0920
    ae974a485f413a2113503eed53cd6c53
    10.1038/sj.bjc.6603521
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    • Authors: Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C, Cunningham D
    • Issue date: 2003 Aug
    • UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
    • Authors: Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G
    • Issue date: 2004 Jan 26
    • Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    • Authors: Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio B, Hahn S, Vaughn D, Thorn C, Whitehead AS, Haller DG, O'Dwyer PJ
    • Issue date: 2004 Mar
    • UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    • Authors: Price T, Hill M
    • Issue date: 2000 Oct
    • Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
    • Authors: Sheikh HY, Valle JW, Waddell T, Palmer K, Wilson G, Sjursen A, Craven O, Swindell R, Saunders MP
    • Issue date: 2008 Aug 19
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.